Gelul are proprietăți reepitelizante și reparatorii, ajutând la vindecarea leziunilor sau micro-leziunilor de la nivelul mucoasei cervico-vaginale și contribuind la restabilirea integrității și a funcționalității normale a acestora.

Hyaluronic acid niosomes): основното им свойство е повърхностно овлажняване на тъканите, придавайки им еластичност. Eficacia en el tratamiento del VPH: Papilocare ha demostrado ser eficaz en la reducción de lesiones cervicales y vaginales causadas por el VPH, así como en la prevención de su reaparición. The results of our study have been replicated in several independent, observational, noncontrolled studies performed in Spanish public university hospitals. 35– 37 The 6-month effectiveness of Papilocare was evaluated and confirmed in all of the studies (between 53% and 72.5% of cases achieved a negative cytology and/or HPV clearance/reduced viral load). An update of the study by Riera et al., 38 which included a watchful waiting control group, revealed a significantly higher percentage of responders in the group treated with Papilocare compared with the controls (80.0% vs 51.4%). Recent interim results from the observational, multicenter, prospective, single-cohort PAPILOBS study (#NTC04199260) revealed a notable effect of Papilocare at 6 months in repairing HPV-dependent low-grade cervical lesions and clearing HPV (66% and 63% of patients, respectively) under real-life conditions. 39 Data obtained in the present study in relation to the HPV clearance, especially in HR HPV patients, are consistent with real-world data obtained in other studies. 40 Moreover, in this trial, the degree of cervical re-epithelization was significantly higher with Papilocare compared with the control group. This beneficial effect on re-epithelization was also observed by Palacios et al. 15 in a pilot study performed with 21 asymptomatic non–HPV-infected women, in which women treated Papilocare achieved improved cervical re-epithelization (from 3.1 to 4.4 according to the same cervical epithelization scoring system used in the present study). Similarly, Gálvez et al. 16 reported a significant 20% improvement in cervical re-epithelialization in HPV-positive lesion-free women treated with Papilocare (3.8 vs 4.5) compared with baseline.Prevención de lesiones cervicales y vaginales: El uso regular de Papilocare ayuda a prevenir la aparición de lesiones relacionadas con el VPH en la zona cervical y vaginal. Papilocare Gel Vaginal 7 canule Gedeon Richter(pentru prevenirea si tratamentul coadjuvant al leziunilor cauzate de HPV) , contine ingrediente active: beta - glucan si poate fi utilizat in baza recomandarii medicului in afecțiuni medicale cum ar fi: infectia cu virusul hpv (human papilloma virus) plante medicinale: extract de coriolus versicolor, extract de neem (azadirachta indica), extract de gotu kola (centella asiatica) contine activi cosmetici: extract de aloe vera cosmetic. En este contexto, surge Papilocare, un innovador producto que ha demostrado ser eficaz en el tratamiento y prevención del VPH y sus complicaciones, especialmente en mujeres. Papilocare ha sido desarrollado para abordar específicamente las lesiones cervicales y vaginales causadas por el VPH, y su uso regular puede ayudar a prevenir la aparición de estas lesiones, mejorando la salud vaginal y reduciendo el riesgo de cáncer. Crearea conditiilor pentru o vindecare rapida a leziunilor cauzate de scarpinat datorita senzatiei de arsura si mancarimii. Approximately 30% of Spanish women younger than 30 years are HPV carriers. 25 The likelihood of HPV infection decreases over time, from 47% between the ages of 15 and 19 years to 12% in women older than 45 years. 26 The HPV is a fundamental factor for the development of cervical cancer. 27 The World Health Organization has recently established the elimination of cervical cancer as a priority medium-term objective. 28 This trial aimed to explore whether treatment with Papilocare provides better results than the conventional watchful waiting strategy in improving low-grade cervical lesions, which are the first step in the natural history of cervical cancer. 29 Clearance of LSILs after a conservative approach is of approximately 59% within 2 years of the diagnosis. Nevertheless, the likelihood of progression of these lesions to a high-grade squamous intraepithelial lesion within 5 years is 12.7%. 30 In addition, treatments for cervical cancer severely compromise the reproductive health of women. In a systematic review of Cochrane, Kyrgiou et al. 31 demonstrated a higher baseline risk for prematurity in women with cervical intraepithelial neoplasia, which increased with excisional and ablative treatments. Therefore, the scenario is conflicting, as choosing an excisional or ablative approach for the treatment of LSILs can result in negative reproductive outcomes, but avoiding treatment and just monitoring the disease results in its progression to high-grade lesions in 12 of 100 women. The current recommendation in Spain also includes monitoring the disease. 32, 33 However, based on the results of this present study, a novel strategy involving Papilocare has become available. The results of this treatment in the repair of low-grade lesions have demonstrated to significantly exceed those obtained with the watchful waiting approach (8 in 10 women achieved a normalization in their lesions).

Papilocare se presenta en forma de gel en un tubo con aplicador, lo que facilita su aplicación y dosificación. El aplicador está diseñado para garantizar una distribución uniforme del gel en la zona vaginal, maximizando su eficacia y minimizando el riesgo de irritación o molestias. El envase de Papilocare contiene suficiente gel para un ciclo completo de tratamiento, y las instrucciones detalladas de uso se incluyen en el prospecto que acompaña al producto. Beneficios de Papilocare Coriolus versicolor grybų ekstraktas, turintis pakartotinio epitelizacijos ir pažeidimų gijimo poveikį ir The percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity. Conclusions

Papilocare® Immunocaps - food supplement with a unique formula

Niosomi de acid hialuronic: actiunea lor principala este hidratarea superficiala a tesuturilor, asigurand elasticitatea. teigiami asmenys su pažeidimais (pažeidimų gydymas ir naujų profilaktika) - rekomenduojama - Papilocare® gelis genitalijų sričiai

hialurónico: Este ingrediente es conocido por sus propiedades hidratantes y regenerativas, ayudando a mantener la mucosa vaginal saludable y protegida. Proceso de compra y envío: Realizar una compra en nuestra farmacia online es sencillo y seguro. Seleccione el producto, agréguelo al carrito de compras y complete la información de envío y pago. Ofrecemos opciones de envío rápidas y confiables para garantizar que reciba su pedido en poco tiempo. The study is a multicenter, open-label, randomized, parallel-group, watchful waiting approach-controlled trial involving 91 HPV-positive women with low-grade Pap smear alterations and consistent colposcopy. ResultsKhông có dữ liệu khi dùng chung với những biện pháp tránh thai như vòng âm đạo. Vì vậy không nên dùng sản phẩm cho những người đang dùng biện pháp trên. Obstetrics and Gynaecology Unit, HM Gabinete Velázquez, C. de Jorge Juan, 19, 1°, 28001 Madrid, Spain. Con su combinación única de ingredientes naturales y científicamente probados, Papilocare trabaja para abordar las lesiones causadas por el VPH, promover un entorno vaginal saludable y reducir el riesgo de cáncer. Los testimonios de pacientes y estudios clínicos respaldan la eficacia y seguridad de este tratamiento.

Estos estudios, junto con el respaldo de ginecólogos y profesionales de la salud, confirman que Papilocare es una opción de tratamiento efectiva y segura para las mujeres afectadas por el VPH y sus complicaciones asociadas. ¿Dónde adquirir Papilocare? Compared with the baseline, the percentual change in the vaginal health index after 3 and 6 months of follow-up was numerically higher in the treatment group (mean percentual change of 2.5% [SD = 13.1] at the 3-month visit and of 3.7% [SD = 15.2] at the 6-month visit) compared with the control group (−0.1% [SD = 10.8], p = .249 and −1.3% [SD = 12.3], p = .067, respectively). A trend toward an improvement in the vaginal health from baseline was observed in the treatment group (41.4% and 42.3% of women achieved an improvement at the 3- and 6-month visit, respectively) in comparison with the control group (31.3% and 29.0%, respectively). Perceived Stress En un estudio clínico publicado en la revista «European Journal of Obstetrics & Gynecology and Reproductive Biology», se encontró que el uso de Papilocare durante 6 meses redujo significativamente la presencia de lesiones cervicales de alto grado en mujeres con VPH. In the PALOMA trial, Papilocare ® demonstrated efficacy in repairing low-grade cervical lesions related to human papillomavirus (HPV). This sub-analysis aimed to evaluate its efficacy in repairing these cervical lesions and clearing HPV in women aged older than 40 years. This was a multicenter, randomized, open-label, parallel-group, controlled clinical trial. Patients with low-degree HPV-dependent cervical lesions receiving 6-month treatment with the vaginal gel were compared to those with a watchful waiting approach. Among the 41 women analyzed (aged 47.7 years), 31 presented high-risk (HR) oncogenic HPV subtypes, and 14 had 16-18-31 HPV genotypes. After 6 months, normalized cytology and concordant colposcopy were achieved by a greater percentage of treated women. The difference was significant in the total population (92.3% vs. 50.0%, p = 0.007), and HR-HPV subpopulation (90.5% vs. 33.3%, p = 0.003). In the HR HPVs-16-18-31 subpopulation, the values were 75.0% and 40.0% ( p = 0.293). In the total population, 61.5% of treated patients obtained HPV clearance, compared to 50.0% in the control group. Regarding the HR-HPV subpopulation, these values were 66.7% and 44.4%, respectively. Papilocare ® demonstrated significant efficacy in repairing low-degree HPV-related cervical lesions and a positive trend to clear HPV in women older than 40 years old in comparison to the watchful waiting approach.Papilocare generalmente es seguro y bien tolerado, pero algunas personas pueden experimentar efectos secundarios leves, como irritación, picazón o enrojecimiento en el área de aplicación. Si experimenta efectos secundarios persistentes o graves, suspenda el uso del producto y consulte a su médico. Výsledky nedávneho výskumu realizovaného vŠpanielsku, ktorý spočíval vo vaginálnej aplikácii gélu obsahujúceho Coriolus versicolor, prezentoval Dr. Damian Dexeus zWomen’s Carmona Dexeus ako prednášku zaradenú vsekcii „Nové pohľady na molekulárnu biológiu abiomarkery“.